{"request_id":"8d79e21bb3fe2c8664a5634857bc236f","results":{"ticker":"BOLD","name":"Boundless Bio, Inc. Common Stock","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0001782303","composite_figi":"BBG00Q4W34T4","share_class_figi":"BBG00Q4W34V1","market_cap":3.540345658e+07,"phone_number":"(858) 766-9912","address":{"address1":"10955 ALEXANDRIA WAY","address2":"SUITE 100","city":"SAN DIEGO","state":"CA","postal_code":"92121"},"description":"Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.","sic_code":"2834","sic_description":"PHARMACEUTICAL PREPARATIONS","ticker_root":"BOLD","homepage_url":"https://www.boundlessbio.com","total_employees":28,"list_date":"2024-03-28","branding":{"logo_url":"https://api.polygon.io/v1/reference/company-branding/Ym91bmRsZXNzYmlvLmNvbQ/images/2025-04-04_logo.png","icon_url":"https://api.polygon.io/v1/reference/company-branding/Ym91bmRsZXNzYmlvLmNvbQ/images/2025-04-04_icon.jpeg"},"share_class_shares_outstanding":22407251,"weighted_shares_outstanding":22407251,"round_lot":100},"status":"OK"}